Table 2.
Clinical characteristics in different groups.
| Characteristics | Non-CHD group (N = 425) | CHD group (N = 231) | p |
|---|---|---|---|
| Age (year） | 58.3 ± 10.7 | 65.3 ± 11.3 | <0.001 |
| Male/female | 168/257 | 104/127 | 0.173 |
| Hypertension (%) | 49.8 | 73.5 | <0.001 |
| DM (%) | 18.6 | 32.5 | <0.001 |
| CCB (%) | 13.2 | 29.4 | <0.001 |
| ACEI/ARB (%) | 12.7 | 28.1 | <0.001 |
| B-blocker (%) | 7.8 | 43.6 | <0.001 |
| Antidiabetic agent (%) | 9.2 | 22.9 | <0.001 |
| Lipid-lowering | 23.1 | 46.3 | <0.001 |
| Agent (%) | |||
| Smoking (%) | 32.2 | 36.4 | 0.285 |
| BMI (kg/m2) | 25.18 ± 3.46 | 25.94 ± 3.57 | 0.008 |
| CFPWV (m/s) | 10.72 ± 2.37 | 11.63 ± 2.52 | <0.001 |
| RABI | 1.125 ± 0.099 | 1.091 ± 0.108 | <0.001 |
| LABI | 1.116 ± 0.107 | 1.099 ± 0.119 | 0.076 |
| SBP (mmHg) | 136.6 ± 19.3 | 141.2 ± 20.0 | 0.004 |
| DBP (mmHg) | 84.1 ± 11.0 | 83.6 ± 11.8 | 0.574 |
| Pulse pressure (mmHg) | 52.4 ± 13.4 | 57.6 ± 15.2 | <0.001 |
| FPG (mmol/L) | 5.82 ± 1.32 | 6.21 ± 2.02 | 0.010 |
| UA (μmol/L) | 304.6 ± 76.5 | 321.5 ± 83.3 | 0.010 |
| Creatinine (μmol/L) | 65.3 ± 19.3 | 67.9 ± 18.9 | 0.089 |
| TC (mmol/L) | 5.02 ± 1.17 | 4.52 ± 1.10 | <0.001 |
| HDL-C (mmol/L) | 1.28 ± 0.33 | 1.14 ± 0.27 | <0.001 |
| LDL-C (mmol/L) | 3.11 ± 0.92 | 2.65 ± 0.82 | <0.001 |
| TG (mmol/L) | 1.77 ± 1.40 | 1.86 ± 2.05 | 0.496 |
| HCY (μmol/L) | 12.73 ± 7.18 | 15.58 ± 7.68 | <0.001 |
| Log NT-proBNP | 1.89–2.31 | 1.99–.57 | <0.001 |
| Log UAE | 0.40–0.91 | 0.47–0.99 | 0.028 |
BMI, body mass index; CFPWV, carotid-femoral pulse wave velocity; RABI, right ankle brachial index; LABI, left ankle brachial index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; UA, uric acid; TC, cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; HCY, homocysteine; UAE, urine albumin (microalbumin) excretion; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.